JP2024538148A - 抗ＥＧＦＲ抗体、抗ｃＭＥＴ抗体、抗ＶＥＧＦ抗体、多重特異性抗体及びそれらの使用 - Google Patents

抗ＥＧＦＲ抗体、抗ｃＭＥＴ抗体、抗ＶＥＧＦ抗体、多重特異性抗体及びそれらの使用 Download PDF

Info

Publication number
JP2024538148A
JP2024538148A JP2024522646A JP2024522646A JP2024538148A JP 2024538148 A JP2024538148 A JP 2024538148A JP 2024522646 A JP2024522646 A JP 2024522646A JP 2024522646 A JP2024522646 A JP 2024522646A JP 2024538148 A JP2024538148 A JP 2024538148A
Authority
JP
Japan
Prior art keywords
seq
heavy chain
nos
light chain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538148A5 (enExample
Inventor
プー プー
ソンリン チャン
イン チン
ピー．マックウィリアムズ マリア
フン マン－チョン
エル．チウ マーク
Original Assignee
タボテック バイオセラピューティクス（ホンコン）リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タボテック バイオセラピューティクス（ホンコン）リミティド filed Critical タボテック バイオセラピューティクス（ホンコン）リミティド
Publication of JP2024538148A publication Critical patent/JP2024538148A/ja
Publication of JP2024538148A5 publication Critical patent/JP2024538148A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024522646A 2021-10-18 2022-10-17 抗ＥＧＦＲ抗体、抗ｃＭＥＴ抗体、抗ＶＥＧＦ抗体、多重特異性抗体及びそれらの使用 Pending JP2024538148A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256705P 2021-10-18 2021-10-18
US63/256,705 2021-10-18
PCT/US2022/078192 WO2023069888A1 (en) 2021-10-18 2022-10-17 ANTI-EGFR ANTIBODIES, ANTI-cMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF

Publications (2)

Publication Number Publication Date
JP2024538148A true JP2024538148A (ja) 2024-10-18
JP2024538148A5 JP2024538148A5 (enExample) 2025-10-22

Family

ID=84267971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522646A Pending JP2024538148A (ja) 2021-10-18 2022-10-17 抗ＥＧＦＲ抗体、抗ｃＭＥＴ抗体、抗ＶＥＧＦ抗体、多重特異性抗体及びそれらの使用

Country Status (8)

Country Link
US (1) US20250230248A1 (enExample)
EP (1) EP4419556A1 (enExample)
JP (1) JP2024538148A (enExample)
KR (1) KR20240099227A (enExample)
CN (1) CN118355030A (enExample)
AU (1) AU2022369278A1 (enExample)
CA (1) CA3232216A1 (enExample)
WO (1) WO2023069888A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4454705A1 (en) * 2023-04-28 2024-10-30 Jost B. Jonas Egfr antagonists for the treatment of diseases involving unwanted migration, proliferation, and metaplasia of retinal pigment epithelium (rpe) cells
EP4746970A1 (en) * 2023-09-12 2026-05-27 Jost B. Jonas Egfr antagonists for the treatment of diseases involving unwanted migration, proliferation, and/or metaplasia of retinal pigment epithelium (rpe) cells
IL328594A (en) * 2023-11-23 2026-07-01 Velavigo Bio Inc Binding molecule and antibody-drug conjugate and their uses
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技（上海）有限公司 一种抗体偶联药物及其用途
CN118085101A (zh) * 2024-03-01 2024-05-28 烟台蓝纳成生物技术有限公司 一种二价双特异性抗体、抗体偶联核素药物及其应用
WO2026098440A1 (zh) * 2024-11-05 2026-05-15 上海齐鲁制药研究中心有限公司 一种双特异性抗体偶联物及其制备方法和应用
WO2026145588A1 (en) * 2024-12-31 2026-07-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Use of egfr/c-met bispecific binding protein

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007042289A2 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
GB0520872D0 (en) * 2005-10-14 2005-11-23 Hofmann Thomas F Onion flavour compounds and use
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN102361884A (zh) 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 双特异性抗-ErbB-2/抗-c-Met抗体
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN106046161B (zh) * 2011-09-30 2019-09-13 埃博灵克斯股份有限公司 与C-Met相关的生物物质
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
EA033463B1 (ru) 2014-11-27 2019-10-31 Panasonic Ip Man Co Ltd Блок стеклянных панелей
JP2019500011A (ja) 2015-11-03 2019-01-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
EP4592313A3 (en) * 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins

Also Published As

Publication number Publication date
KR20240099227A (ko) 2024-06-28
WO2023069888A1 (en) 2023-04-27
US20250230248A1 (en) 2025-07-17
AU2022369278A1 (en) 2024-05-02
CN118355030A (zh) 2024-07-16
EP4419556A1 (en) 2024-08-28
CA3232216A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
US12157771B2 (en) Proteins binding NKG2D, CD16 and CLEC12A
US20250230248A1 (en) Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof
EP3559040B1 (en) Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 (trailr2) and anti-cadherin 17 (cdh17) binding molecules for the treatment of cancer
AU2019356806B2 (en) Antibody constructs binding 4-1BB and tumor-associated antigens and uses thereof
JP2022513653A (ja) 修飾された重鎖定常領域を含む抗体
US20250277051A1 (en) Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
TW202216767A (zh) 與ＣＤ３及ＦｏｌＲ１結合之抗體
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
JP2025542239A (ja) 自己免疫疾患の治療
AU2024254039A1 (en) Hinge-modified bispecific antibodies
JP2022540846A (ja) Ｔｎｆ－アルファおよびｉｌ－１ベータに対する二特異性抗体ならびにその使用
US20240150480A1 (en) Binding molecules for the treatment of cancer
WO2025201242A1 (en) Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof
WO2025201240A1 (en) Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
US20260109769A1 (en) Pd-1 bnding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use
US20220153869A1 (en) Shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereof
KR20260054696A (ko) 면역접합체를 포함하는 약학적 조성물 및 이의 용도
WO2026080748A2 (en) Bone morphogenetic protein receptor type 2 (bmprii) antibodies
WO2026080757A2 (en) Activin receptor type ii a/b (actriia/b) antibodies
AU2024276812A1 (en) Bispecific agonistic antibodies to il12 receptor
CA3300901A1 (en) Pharmaceutical composition containing immunoconjugate and use thereof
CN119213034A (zh) 双功能蛋白质及其制剂和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251010